Please assess the completion status of the following clinical trial:

Trial Title: Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent prior to any screening procedures~* Male or female patients ≥ 18 years of age~* Patient must weigh between 45-135 kg~* Patients with low or intermediate (int-1) risk MDS, as determined by IPSS score or RA, RARS by WHO criteria. IPSS must be confirmed by a bone marrow examination within 6 months prior to study entry and must be hematologically stable~Deferasirox naïve:~Sexually active pre-menopausal female patients must use double-barrier contraception, oral contraceptive plus barrier contraceptive, or must have undergone clinically documented total hysterectomy and/or oophorectomy, tubal ligation~Exclusion Criteria:~* History or current GI disease~* Systemic diseases which could prevent study treatments~* Left ventricular ejection fraction\< 50 % by echo cardiography~* Serum creatinine \> 1.2 x ULN at screening~* Platelet counts \< 25x 109/L except in cases where guidance is already given in the local deferasirox label~* AST or ALT \> 2.5 xULN at screening~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Deferasirox am (Type: EXPERIMENTAL): Deferasirox 20 mg/kg/day taken in the morning, 30 minutes before food
- Deferasirox pm (Type: EXPERIMENTAL): Deferasirox 20 mg/kg/day taken in the evening, no less than 2 hours after the last food intake or at least 30 minutes before the evening meal

Based on this trial design, predict the completion outcome and termination type (if applicable).